CAS: 879085-55-9; 2-Chloro-N-(4-Chloro-3-(Pyridin-2-yl)Phenyl)-4-(Methylsulfonyl)Benzamide

该化合物是一种小分子抑制剂,它针对的是格列猪信号路径,专门设计用来治疗某些类型的癌症,特别是巴萨细胞癌.它被归类为刺绣路径抑制剂,通过阻塞滑动活动来工作,这是途径中的一种蛋白质,从而防止癌症细胞的扩散.Vismodegib 通常通过口述方式施用,并因其在治疗已迁移或当地先进且无法外科移除的高级巴萨细胞癌方面的作用而闻名.该化合物的分子配方反映了其复杂结构,包括多种功能组,有助于其药理活动.与Vismodigib 相关的共同副作用包括肌肉抽筋,发毛和胃肠扰动.由于它的操作机制,它也正在研究其是否可用于其他恶性肿瘤,与畸形刺猪信号有关.与任何药物一样,它的使用应该受到保健专业人员的密切监测,以管理任何不利影响并确保治疗功效.

结构式图片

欧盟法规

C&L通报

上下游产品

2-(3-nitrophenyl)pyridine 2-(2-chloro-5-nitrophenyl)-pyridine 4-chloro-3-(pyridin-2-yl)benzeneamine 2-chloro-4-(methylsulphonyl)benzoyl chloride

合成工艺路线路线简述

  • 101349-95-5 + 879088-41-2 = 879085-55-9
    反应条件:1.1 Solvents: Methanol; Reflux1.2 Reagents: Potassium Tert-Butoxide,Oxygen,1H-Imidazolium,3-Ethyl-1-Methyl-,Tetrafluoroborate(1-) (9:10) Solvents: 1,4-Dioxane; Rt
    标题:From Imines To Amides Via Nhc-Mediated Oxidation
    作者:Sun,Shaofa; Et Al
    参考文献:Organic Chemistry Frontiers 日期:2022 卷标:9(2) 页码:356-363]

    2759099-84-6 = 879085-55-9
    反应条件:1.1 Reagents: Potassium Tert-Butoxide,Oxygen,1H-Imidazolium,3-Ethyl-1-Methyl-,Tetrafluoroborate(1-) (9:10) Solvents: 1,4-Dioxane; 2 H,Rt
    标题:From Imines To Amides Via Nhc-Mediated Oxidation
    作者:Sun,Shaofa; Et Al
    参考文献:Organic Chemistry Frontiers 日期:2022 卷标:9(2) 页码:356-363]

    106904-10-3 + 1195072-76-4 = 879085-55-9
    反应条件:1.1 Reagents: Sulfuric Acid Solvents: Water; 24 H,100 °C; 100 °C -> Rt1.2 Reagents: Sodium Carbonate Solvents: Water; Neutralized,Rt1.3 Reagents: Triethylamine Solvents: Tetrahydrofuran; 0 °C; 16 H,Rt
    标题:Directed Meta-Selective Bromination Of Arenes With Ruthenium Catalysts
    作者:Yu,Qingzhen; Et Al
    参考文献:Angewandte Chemie 日期:2015 卷标:54(50) 页码:15284-15288]

    80-48-8 + 2408320-20-5 = 879085-55-9
    反应条件:1.1 Reagents: Tin,Sodium Pyrosulfite,Dipotassium Phosphate Catalysts: Tetrabutylammonium Bromide,1,1-Bis(Diphenylphosphino)Ferrocene,[1,1′-Bis(Diphenylphosphino)Ferrocene]Dichloropalladium Solvents: Dimethyl Sulfoxide; 10 H,100 °C
    标题:Multicomponent Reductive Cross-Coupling Of An Inorganic Sulfur Dioxide Surrogate: Straightforward Construction Of Diversely Functionalized Sulfones
    作者:Meng,Yingying; Et Al
    参考文献:Angewandte Chemie 日期:2020 卷标:59(3) 页码:1346-1353]

    879088-41-2 = 879085-55-9 [标题:Reaction Conditions
    标题:Selective Hydrogenation Of Halogenated Nitroaromatics To Haloanilines In Batch And Flow
    作者:Loos,Patrick; Et Al
    参考文献:Organic Process Research & Development 日期:2016 卷标:20(2) 页码:452-464]

    106904-10-3 + 573764-31-5 = 879085-55-9
    反应条件:1.1 Solvents: Dimethylacetamide; Rt; 40 Min,40 °C2.1 Catalysts: Dichlorobis(Triphenylphosphine)Palladium Solvents: N-Methyl-2-Pyrrolidone; 20 Min,130 °C
    标题:Design,Synthesis And Biological Evaluation Of Deuterated Vismodegib For Improving Pharmacokinetic Properties
    作者:Wang,Fangying; Et Al
    参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2018 卷标:28(14) 页码:2399-2402]

    55-21-0 + 1245636-12-7 = 879085-55-9
    反应条件:1.1 Reagents: N,N,N′,N′-Tetramethylethylenediamine Catalysts: Cuprous Iodide Solvents: 1,4-Dioxane; 24 H,100 °C2.1 Reagents: Sulfuric Acid Solvents: Water; 24 H,100 °C; 100 °C -> Rt2.2 Reagents: Sodium Carbonate Solvents: Water; Neutralized,Rt2.3 Reagents: Triethylamine Solvents: Tetrahydrofuran; 0 °C; 16 H,Rt
    标题:Directed Meta-Selective Bromination Of Arenes With Ruthenium Catalysts
    作者:Yu,Qingzhen; Et Al
    参考文献:Angewandte Chemie 日期:2015 卷标:54(50) 页码:15284-15288]

    106904-10-3 + 879088-41-2 = 879085-55-9
    反应条件:1.1 Reagents: Potassium Carbonate Solvents: Tetrahydrofuran,Water; 35 Min,2 °C; 2 °C -> 20 °C
    标题:Manufacturing Development And Genotoxic Impurity Control Strategy Of The Hedgehog Pathway Inhibitor Vismodegib
    作者:Angelaud,Remy; Et Al
    参考文献:Organic Process Research & Development 日期:2016 卷标:20(8) 页码:1509-1519]

    53250-83-2 + 879088-41-2 = 879085-55-9
    反应条件:1.1 Reagents: Triethylamine,Thionyl Chloride Solvents: Tetrahydrofuran; Rt; 30 Min,Rt -> Reflux
    标题:Synthesis Of Vismodegib,A Hedgehog Signaling Pathway Inhibitor
    作者:Li,Yan-Yang; Et Al
    参考文献:Zhongguo Xinyao Zazhi 日期:2013 卷标:22(17) 页码:2090-2092]

    = 879085-55-9
    反应条件:1.1 Reagents: Potassium Peroxymonosulfate Sulfate (2Khso5.Khso4.K2So4) Solvents: Methanol,Water; Rt
    标题:Palladium-Catalyzed Thiomethylation Via A Three-Component Cross-Coupling Strategy
    作者:Wang,Ming; Et Al
    参考文献:Organic Letters 日期:2018 卷标:20(19) 页码:6193-6197]

    = 879085-55-9
    反应条件:1.1 Reagents: O-Xylene,Water,Oxygen Catalysts: Uranyl Acetate Solvents: Acetonitrile; Rt1.2 Reagents: Sodium Bicarbonate Solvents: Water; 10 Min,Rt1.3 Reagents: Sulfuric Acid Magnesium Salt (1:1); 10 Min,Rt
    标题:Selective Late-Stage Oxygenation Of Sulfides With Ground-State Oxygen By Uranyl Photocatalysis
    作者:Li,Yiming; Et Al
    参考文献:Angewandte Chemie 日期:2019 卷标:58(38) 页码:13499-13506]

    17997-47-6 + 1314306-02-9 = 879085-55-9
    反应条件:1.1 Catalysts: Dichlorobis(Triphenylphosphine)Palladium Solvents: N-Methyl-2-Pyrrolidone; 20 Min,130 °C
    标题:Design,Synthesis And Biological Evaluation Of Deuterated Vismodegib For Improving Pharmacokinetic Properties
    作者:Wang,Fangying; Et Al
    参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2018 卷标:28(14) 页码:2399-2402]

    1079360-49-8 + 879088-41-2 = 879085-55-9
    反应条件:1.1 Reagents: Thionyl Chloride Solvents: Dimethylformamide,Toluene1.2 Reagents: Potassium Carbonate Solvents: Tetrahydrofuran2.1 Reagents: O-Xylene,Water,Oxygen Catalysts: Uranyl Acetate Solvents: Acetonitrile; Rt2.2 Reagents: Sodium Bicarbonate Solvents: Water; 10 Min,Rt2.3 Reagents: Sulfuric Acid Magnesium Salt (1:1); 10 Min,Rt
    标题:Selective Late-Stage Oxygenation Of Sulfides With Ground-State Oxygen By Uranyl Photocatalysis
    作者:Li,Yiming; Et Al
    参考文献:Angewandte Chemie 日期:2019 卷标:58(38) 页码:13499-13506]

    1461-22-9 + 109-04-6 = 879085-55-9
    反应条件:1.1 Reagents: Butyllithium Solvents: Tetrahydrofuran; -78 °C; 30 Min,-78 °C1.2 -78 °C; 1 H,-78 °C; -78 °C -> Rt; 1 H,Rt1.3 Reagents: Ammonium Chloride Solvents: Water; Rt2.1 Catalysts: Dichlorobis(Triphenylphosphine)Palladium Solvents: N-Methyl-2-Pyrrolidone; 20 Min,130 °C
    标题:Design,Synthesis And Biological Evaluation Of Deuterated Vismodegib For Improving Pharmacokinetic Properties
    作者:Wang,Fangying; Et Al
    参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2018 卷标:28(14) 页码:2399-2402]

    1195072-76-4 = 879085-55-9
    反应条件:1.1 Reagents: Sulfuric Acid Solvents: Water; 24 H,100 °C; 100 °C -> Rt1.2 Reagents: Sodium Carbonate Solvents: Water; Neutralized,Rt2.1 Reagents: Triethylamine Solvents: Tetrahydrofuran; 0 °C; 16 H,Rt
    标题:Directed Meta-Selective Bromination Of Arenes With Ruthenium Catalysts
    作者:Yu,Qingzhen; Et Al
    参考文献:Angewandte Chemie 日期:2015 卷标:54(50) 页码:15284-15288
2-(2-Chlorophenyl)Pyridine置于二茂铁,2,6-二叔丁基吡啶,3,5-二氟-2-吡啶羧酸,六氟异丙醇,Potassium Carbonate体系中,用 四氢呋喃,水 作为反应溶剂,化学反应 72.08H,反应生成 2-氯-N-[4-氯-3-(2-吡啶基)苯基]-4-(甲磺酰基)苯甲酰胺
参考文献:通过非共价相互作用推进元选择性 C-h 胺化
标题:通过非共价相互作用推进元选择性 C-h 胺化
摘要:简单芳烃的区域选择性 C-H 胺化是非常理想的,但由于缺乏电子和空间偏好,访问普遍存在的芳烃的元位点已被证明具有挑战性.这项研究证明了成功地利用药物化合物中发现的各种独特的含氮官能团来指导芳烃的间-C-H胺化,克服了长期以来对冗余导向基团的要求.通过发现前所未有的有机引发剂和非共价相互作用的战略利用,在精确区域化学控制的官能团调节方面取得了显着进展.该方案已成功应用于药物分子的简洁合成和后期衍生化,否则这是很难实现的.
DOI:10.1021/jacs.3C09904

海关参考信息

专利信息


专利号:US-12221452-B2
优先权日:2017-10-04
标题:Synthesis of cantharidin
发明人:DAVIDSON MATTHEW GENE; EKLOV BRIAN MATTHEW; WUTS PETER; LOERTSCHER BRAD MELVIN; SCHOW STEVEN R
权利人:VERRICA PHARMACEUTICALS INC
摘要:The invention provides synthetic methods for the preparation of cantharidin and analogs thereof. In one aspect, the invention provides an improved Diels-Alder cycloaddition to generate a key intermediate en route to cantharidin and analogs thereof. In certain embodiments, the new Diels-Alder reaction involves reacting Compound (2) in the presence of furan, and in the absence of acid or increased pressure, in an aprotic polar solvent with slight warming, to yield Compound (1) in favorable yield and exo-endo ratio. In another aspect, the invention also provides a new Diels-Alder reaction between compounds of Formula (III) and furan to yield compounds of Formula (IV), which can then be transformed into cantharidin or analogs thereof. In yet another aspect, the invention describes a new palladium-mediated carbonylation providing another key intermediate en route to cantharidin and analogs thereof. In addition to synthetic methods, present invention also provides compounds (i.e., intermediates) useful in the synthesis of cantharidin and analogs thereof. Compounds provided herein may have biological activity, and therefore may be used in the treatment of diseases or conditions (e.g., infectious diseases and skin conditions).

专利号:US-2025206743-A1
优先权日:2022-03-25
标 题:Tyk2 inhibitor synthesis and intermediates thereof
发明人:MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG
权利人:TAKEDA PHARMACEUTICALS CO
摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.

专利号:US-8828984-B2
优先权日:2012-11-19
标题:Gold(III) complexes containing N-heterocyclic carbene ligand, synthesis, and their applications in cancer treatment and thiol detection
发明人:CHE CHI MING; ZOU TAOTAO
权利人:UNIV HONG KONG; UNIV HONG KONG
摘要:Provided herein is a method of synthesis of Au(III)-NHC complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Au(III)-NHC complexes. Also provided is method of detecting thiol in a biological system. The Au(III)-NHC complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase activity, and inhibition of tumor growth in vivo.

专利号:US-10577387-B1
优先权日:2018-08-09
标题 :Platinum (II) complexes containing N-heterocyclic carbene ligand and pincer ligands, synthesis, and their applications in cancer treatment
发明人:CHE CHI MING; Fung Sin Ki; Chen tian feng
权利人:UNIV HONG KONG
摘要:Provided herein is a method of synthesis of Pt(II) complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Pt(II) complexes. Also provided is a method of detecting the Pt(II) complex in a biological system. Also provided is a method of making the Pt(II) complex The Pt(II) complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, and inhibition of tumor growth in vivo.

专利号:US-11286271-B2
优先权日:2018-07-31
标 题 :Iridium (III) complexes containing N-heterocyclic carbene ligand, synthesis, and their use thereof in cancer treatment
发明人:CHE CHI MING; LAM TSZ LUNG; TONG KA CHUNG
权利人:UNIV HONG KONG
摘要:Provided herein are Ir(III) complexes comprising N-heterocyclic carbene ligand, method of synthesis of the Ir(III) complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Ir(III) complexes under both dark and light conditions. Also provided is a method of detecting the Ir(III) complex in a biological system. Also provided is a method of making the Ir(III) complex. The Ir(III) complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, and inhibition of tumor growth in vivo.

专利号:WO-2024262824-A1
优先权日:2023-06-20
标 题 :Novel process for synthesis of polysubstituted pyridine derivatives
发明人:PARK SEUNG BUM; YI SIHYEONG
权利人:SEOUL NAT UNIV R&DB FOUNDATION
摘要:The present invention relates to a novel method for synthesizing a polysubstituted pyridine derivative and, more specifically, to a method for synthesizing a 2,3,5-substituted pyridine derivative through a specific ring cleavage reaction. In the synthesis method of the present invention, an enamine structure is formed in situ by using beta keto ester/sulfone/phosphonic acid ester and ammonium acetate and subjected to an aldol condensation reaction with 3-formyl (aza) indole/benzofuran, a cyclization reaction, and a ring-cleavage reaction in that order to synthesize a characteristic pyridine structure having an alkyl/aryl substituent attached to the 2-position thereof, an ester/sulfone/phosphonic acid ester attached to the 3-position thereof, and ortho-aminoaryl/phenol including various substituents attached to the 5-position thereof. In particular, (aza)indole/benzofuran and beta keto ester/sulfone/phosphonic acid ester, which are reaction substrates, are substrates having very high accessibility, and enable the introduction of various substituents, thereby constructing a pyridine skeleton having high biocompatibility into which ortho-aminoaryl or phenol substituents having various substituents are introduced.
成都格蓝洋生物医药科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.glykj.com
电话: 86+28-85337952 18081025021👤
📞成都格蓝洋生物医药科技有限公司 ⚠️参考联系方式

销售电话:86+28-85337952 18081025021
邮箱:greenyoung@glykj.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:成都高新区天府大道北段1480号天河孵化园一号楼B-026
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
台州市科瑞生物技术有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.pharm-intermediates.com
企业联系电话:0576-88813233👤
📞台州市科瑞生物技术有限公司 ⚠️参考联系方式
联系人:金崇光
电话:0576-88813233
手机:13396860566
传真:0576-88813233
邮箱:sales@pharm-intermediates.com
通信地址: 台州市开发大道东段288号
邮编: 318000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:台州市开发大道东段288号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
安徽万和制药有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.wanhegroup.com/fb-4/about.htm
电话: 021-53083188👤
📞安徽万和制药有限公司 ⚠️参考联系方式

销售电话:021-53083188
邮箱:info@wanhegroup.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
宁波英特格瑞生物科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.integrity-bio.com
企业联系电话:0574-86822786👤
📞宁波英特格瑞生物科技有限公司 ⚠️参考联系方式
联系人:石经理
电话:0574-86822786
手机:15824278467
传真:0574-86821822
邮箱:sales@integrity-bio.com
通信地址: 宁波北仑区明州路731号长江国际A座1209室
邮编: 315000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:宁波北仑区明州路731号长江国际A座1209室
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Poggi L, Kolesar JM. Vismodegib for the treatment of basal cell skin cancer. Am J Health Syst Pharm. 2013 Jun 15;70(12):1033-8. doi: 10.2146/ajhp120311. Review. Review. doi: 10.1016/j.clinthera.2012.08.011. Epub 2012 Oct 1. Review. doi: 10.1358/dot.2012.48.7.1808490. Review. doi: 10.2165/11209590-000000000-00000. Review. Review.

合成参考文献


参考文献:10.1158/1078-0432.ccr-11-0972
摘要:Lorusso PM, Jimeno A, Dy G, Adjei A, Berlin J, Leichman L, Low JA, Colburn D, Chang I, Cheeti S, Jin JY, Graham RA. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 2011 Sep 01;17(17):5774–82. doi: 10.1158/1078-0432.ccr-11-0972.
参考文献:10.1158/0008-5472.can-11-0923
摘要:Metcalfe C, de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res. 2011 Aug 01;71(15):5057–61. doi: 10.1158/0008-5472.can-11-0923.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知